Recombinant Cell Platform for Pain Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying drug candidates for pain treatment are hindered by the inaccessibility of neurons that transduce painful stimuli, and primary cells from postmortem neural samples have short lifespans and do not proliferate in vitro, limiting the development of effective pain treatments.
Innovation Solution
A recombinant cell capable of proliferating in vitro, expressing a polypeptide with sequence identity to PRDM12, is used to evaluate drug candidates by assessing electrophysiological, proteomic, transcriptomic, or other characteristics, enabling the identification of effective pain treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary cells from postmortem neural samples are used, then the cells can be obtained from human tissue, but the cells have short lifespans and do not proliferate in vitro
Solution Approach 1:
The patent creates recombinant neural cells that replicate the functional and phenotypic characteristics of primary nociceptive neurons in vitro. These recombinant cells express pain-related genes and receptors, enabling them to respond to noxious stimuli similarly to primary cells, while overcoming the limitation of primary cells having short lifespans and inability to proliferate.
Solution Approach 2:
The patent modifies cellular parameters by introducing specific recombinant genes (such as PRDM12, NTRK1, or other nociceptive markers) into host cells to transform them into functional nociceptive-like cells. This genetic parameter change enables the cells to exhibit pain-sensing capabilities while maintaining proliferative capacity and extended lifespan in culture.
2Measurement precision
If neurons that transduce painful stimuli are used, then the cells can directly evaluate pain treatment efficacy, but the cells are inaccessible for in vitro study
Solution Approach 1:
The recombinant cells serve as intermediary models that bridge the gap between inaccessible primary nociceptive neurons and in vitro drug testing systems. These cells are engineered to express pain-related markers and respond to nociceptive stimuli, allowing researchers to study pain mechanisms and test analgesic drugs in a controlled in vitro environment without needing to access living neural tissue.
Solution Approach 2:
The patent develops in vitro cell models that copy the essential functional properties of nociceptive neurons, including expression of pain receptors (TRPV1, TRPA1), ion channels, and neurotransmitter systems. This copying enables direct evaluation of pain treatment efficacy through electrophysiological recordings, calcium imaging, and behavioral assays in a accessible in vitro platform.
3Reliability
If current pain treatments are used, then pain can be managed, but the treatments are addictive and lose efficacy over time
Solution Approach 1:
The recombinant cells enable self-contained in vitro pain modeling systems that can continuously evaluate multiple drug candidates without requiring animal models or human clinical trials for initial screening. The cells maintain stable pain-sensing functionality over time, providing a reliable platform for assessing long-term efficacy and safety of potential analgesics without the constraints of animal ethics or human variability.
Data Source
AI summary
Provided herein is a recombinant cell for drug candidate screening. Also provided herein is a method of producing the recombinant cell, and a method of identifying a drug candidate comprising providing the recombinant cell.